Publications by authors named "Harada Mirii"

Claim this Profile
C
Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes.
Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna

Oncol Lett· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor.
Mirii Harada, Ikko Tomisaki, Shohei Shimajiri, Keisuke Kuretake, Kenichi Harada

IJU Case Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Mirii Harada

Anticancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna

Int J Urol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Akinori Minato, Rieko Kimuro, Daichi Ohno, Kentarou Tanigawa, Keisuke Kuretake, Mirii Harada

Anticancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna

Anticancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Akinori Minato, Ikko Tomisaki, Rieko Kimuro, Katsuyoshi Higashijima, Mirii Harada

Nihon Hinyokika Gakkai Zasshi· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Mirii Harada

Onco Targets Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Akinori Minato, Nobuki Furubayashi, Mirii Harada, Takahito Negishi, Naotaka Sakamoto

Clin Genitourin Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Mirii Harada

Cancer Manag Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Ikko Tomisaki, Mirii Harada, Akinori Minato, Yujiro Nagata, Rieko Kimuro

Anticancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Akinori Minato, Hirotsugu Noguchi, Rieko Kimuro, Harada Mirii, Nagata Yujiro

Anticancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Naohiro Fujimoto, Kenichi Harada, Masaki Shiota, Ikko Tomisaki, Akinori Minato, Mirii Harada

Anticancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
Ikko Tomisaki, Mirii Harada, Kei Tokutsu, Akinori Minato, Yujiro Nagata

In Vivo· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Mirii Harada, Ikko Tomisaki, Akinori Minato, Rei Onishi, Michikazu Terado

Int J Urol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis